Top SitesCancerNetwork - Oncology News and Clinical Expertise

Machine Readiness

Stored receipt and evidence

Overall

20

Readable

65

Callable

0

Commerce

0

Payment

0

Machine Access

Inspect the site's MCP endpoint

Open MCP explorer

DialtoneApp can scan the stored discovery files for this domain, try the MCP initialize handshake, and show the raw protocol transcript.

Purchase boundary

read only

Control boundary

unknown

Payment rails

None

Payment providers

None

Payment methods

None

Payment protocols

None

Payment assets

None

Payment networks

None

Capabilities

None

Verified payment surface

No

Crypto only

No

Readable docs

robots, llms

Products

0

Variants

0

Priced variants

0

Currencies

0

Offers

0

Priced offers

0

Priced actions

0

Samples

Offer samples

No stored offer samples.

Samples

Action samples

No stored action samples.

Samples

Product samples

No stored product samples.

Document

robots.txt

Open robots.txt
User-agent: *
Disallow: /search
Disallow: /preview/
Disallow: /*[*]*$
Sitemap: https://www.cancernetwork.com/sitemap.xml
Sitemap: https://www.cancernetwork.com/sitemap-news.xml
Sitemap: https://www.cancernetwork.com/sitemap-videos.xml

Document

llms.txt

Open llms.txt
# CancerNetwork

> CancerNetwork - Healthcare Publication

- Base URL: https://www.cancernetwork.com
- Generated: 2026-04-25T02:47:36.208Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.cancernetwork.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.cancernetwork.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cancernetwork.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.cancernetwork.com/robots.txt](https://www.cancernetwork.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Around the Practice](https://www.cancernetwork.com/around-the-practice)
- [Between the Lines](https://www.cancernetwork.com/between-the-lines)
- [Breaking Barriers](https://www.cancernetwork.com/breaking-barriers)
- [Clinical](https://www.cancernetwork.com/clinical)
- [Clinical Consult](https://www.cancernetwork.com/clinical-consult)
- [Conference](https://www.cancernetwork.com/conference)
- [Face-Off](https://www.cancernetwork.com/face-off)
- [From All Angles](https://www.cancernetwork.com/from-all-angles)
- [Frontline Forum](https://www.cancernetwork.com/frontline-forum)
- [Global Bulletin](https://www.cancernetwork.com/global-bulletin)
- [Hero](https://www.cancernetwork.com/hero)
- [Integrative Care](https://www.cancernetwork.com/integrative-care)
- [Media](https://www.cancernetwork.com/media)
- [Meeting of the Minds](https://www.cancernetwork.com/meeting-of-the-minds)
- [Men's Health](https://www.cancernetwork.com/mens-health)
- [News](https://www.cancernetwork.com/news)
- [OncView](https://www.cancernetwork.com/k-cast)
- [Podcasts](https://www.cancernetwork.com/podcasts)
- [Publications](https://www.cancernetwork.com/journals)
- [Quizzes](https://www.cancernetwork.com/resources/quizzes)
- [Readout 360](https://www.cancernetwork.com/readout-360)
- [Resources](https://www.cancernetwork.com/resources)
- [Roles](https://www.cancernetwork.com/roles)
- [The Bispecifics Network](https://www.cancernetwork.com/the-bispecific-network)
- [Training Academy](https://www.cancernetwork.com/training-academy)
- [Treatment Algorithms with the Oncology Brothers](https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers)
- [Tumor Board Series](https://www.cancernetwork.com/tumor-board-series)
- [Video Series](https://www.cancernetwork.com/video-series)
- [Videos](https://www.cancernetwork.com/videos)
- [Webinars](https://www.cancernetwork.com/webinars)
- [Year in Review](https://www.cancernetwork.com/year-in-review)

## Featured Content

- [This Week in Oncology: Real-World NSCLC Care and AACR 2026 Updates](https://www.cancernetwork.com/view/this-week-in-oncology-real-world-nsclc-care-and-aacr-2026-updates): Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases like NSCLC and oral premalignant lesions.
- [Taletrectinib Data Affirm Importance of Molecular Testing in NSCLC](https://www.cancernetwork.com/view/taletrectinib-data-affirm-importance-of-molecular-testing-in-nsclc): Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.
- [Examining Conversative Management in Low/Intermediate-Risk Prostate Cancer](https://www.cancernetwork.com/view/examining-conversative-management-in-low-intermediate-risk-prostate-cancer): Recently, conservative management has grown in popularity, especially among older patients and those with higher neighborhood-level socioeconomic stat...
- [Discussing Proper Utilization of BCMA Bispecifics in Early Relapse Multiple Myeloma](https://www.cancernetwork.com/view/discussing-proper-utilization-of-bcma-bispecifics-in-early-relapse-multiple-myeloma): A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.
- [Future Directions and Unmet Needs in EGFR Mutated Metastatic Non-Small Cell Lung Cancer](https://www.cancernetwork.com/view/future-directions-and-unmet-needs-in-egfr-mutated-metastatic-non-small-cell-lung-cancer): In this closing segment, the panel reflects on ongoing unmet needs in the first line management of EGFR mutated metastatic non-small cell lung cancer.
- [Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus–Positive DLBCL: A Rare Concomitant Association](https://www.cancernetwork.com/view/adult-t-cell-leukemia-lymphoma-and-epstein-barr-virus-positive-dlbcl-a-rare-concomitant-association)
- [Redefining Long Term Success in EGFR Mutated Metastatic Non-Small Cell Lung Cancer](https://www.cancernetwork.com/view/redefining-long-term-success-in-egfr-mutated-metastatic-non-small-cell-lung-cancer): In this segment, the discussion returns to the theme of long term management in EGFR mutated metastatic non-small cell lung cancer. 
- [European Commission Approves Tovorafenib in BRAF+ Pediatric Low-Grade Glioma](https://www.cancernetwork.com/view/european-commission-approves-tovorafenib-in-braf-pediatric-low-grade-glioma): The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from...
- [Shifting Paradigms in the Surgical and Systemic Management of RCC](https://www.cancernetwork.com/view/shifting-paradigms-in-the-surgical-and-systemic-management-of-rcc): Patrick A. Kenney, MD, and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.
- [The Synergy of Early Detection and KRAS Inhibition in Pancreatic Cancer](https://www.cancernetwork.com/view/the-synergy-of-early-detection-and-kras-inhibition-in-pancreatic-cancer): According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.

## Feeds and Indexes

- [RSS Feed](https://www.cancernetwork.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cancernetwork.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cancernetwork.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cancernetwork.com/authors): Browse all contributors and their published work

Document

llms-full.txt

Not stored for this site.